|
DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Seagen; Skyline Diagnostics; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen Oncology; Takeda |
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen Oncology; Pharmacyclics; Sanofi; Seagen |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genesis Pharmaceuticals; Janssen-Cilag; Medison; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Genesis Pharmaceuticals; Janssen-Cilag; Takeda |
Research Funding - Amgen (Inst); Genesis Pharmaceuticals (Inst); Janssen-Cilag (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Genesis Pharmaceuticals; Janssen-Cilag; Takeda |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline; GlaxoSmithKline |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |